394 results about "Dyskinesia" patented technology

For Parkinson's patients to function at their best, their medications need to be optimally adjusted to the diurnal variation of symptoms. For this to occur, it is important for the managing clinician to have an accurate picture of how the patient's bradykinesia / hypokinesia and dyskinesia and the patient's perception of movement state fluctuate throughout the normal daily activities. The present invention uses wearable accelerometers coupled with computer implemented learning and statistical analysis techniques in order to classify the movement states of Parkinson's patients and to provide a timeline of how the patients fluctuate throughout the day.

The invention relates to the improvement in the treatment of certain neural disorders / diseases, such as Parkinson's disease and other motor disorders. The invention relates to drug compositions and dosage forms comprising said drug composition; methods of manufacturing the drug compositions and dosage forms; and methods of treatment, comprising administering the drug composition and dosage form to an individual. In certain embodiments, the drug compositions and dosage forms comprise carbidopa and levodopa in a formulation suitable for once-daily administration.

A method for reducing left ventricular volume, which comprises identifying infarcted tissue during open chest surgery; reducing left ventricle volume while preserving the ventricular apex; and realigning the ventricular apex, such that the realigning step comprises closing the lower or apical portion of said ventricle to achieve appropriate functional contractile geometry of said ventricle in a dyskinetic ventricle of a heart.

Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and / or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and / or Parkinson's disease or any combinations.

The invention provides a method, and dosage form therefor, of treating impaired motor function associated with Parkinson's disease, anti-Parkinson's drug treatment, e.g. L-Dopa therapy, and / or dementia associated with Parkinson's disease. The invention includes the combined administration of an NMDA receptor antagonist and an antidepressant, e.g., the combination of amantadine and citalopram or venlafaxine, or an NMDA receptor antagonist and an anxiolytic agent, e.g., amantadine and buspirone or trazodone, for the amelioration of undesired tremors, akinesia, dyskinesia, or bradykinesia associated with one or more different disorders or diseases. The drugs can be included in a single dosage form. One embodiment includes a combination dosage form containing each drug in controlled release forms. Another embodiment includes a combination dosage form providing a controlled release of an NMDA receptor antagonist and a rapid release of a neuroactive agent after administration to a subject.

Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A / 2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A / 2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A / 2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A / 2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

The invention relates to hand function rehabilitation training equipment based on a spontaneous movement imagery electroencephalograph. Hardware of the instrument consists of an electroencephalograph signal acquisition and processing module, a hand force signal real-time detection sensor array, a control module based on multisource information fusion and a rehabilitation manipulator module, and software for supporting the active rehabilitation training of hand functions is arranged in a computer. The rehabilitation training equipment provides external compensation assistance or resistance hierarchically by taking movement imagery electroencephalographs of patients who suffer from cerebral injury as a starting signal and the muscle force of hands as a feedback signal in a self-adaptive mode according to the myasthenia state of the patients to assist patients who suffer from dyskinesia in performing passive, assisted and active rehabilitation training, displays the state information of the hand movement functions and the provided external power information for doctors and the patients and provides an objective and quantitative assessment method and an index for clinical rehabilitation diagnosis and treatment. The instrument is easy to use, has a friendly interface and is accepted by the doctors and the patients easily. A user can operate a system of the instrument without programming experiences, and the operating environment is not complex.

A compound of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Tetrahydropiperidyl Compound”); compositions comprising an effective amount of a Tetrahydropiperidyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Tetrahydropiperidyl Compound are disclosed herein.

A recovery walking aiding robot belongs to walking aiding robots and recovery machinery, solves the problem that an existing recovery walking aiding robot is inflexible to pass through the narrow environment, simple in motion function and high in requirements for operation flexibility of users, and well meets actual recovery requirements. The recovery walking aiding robot comprises a handrail frame, a connection frame, a flat type microcomputer, an S-shaped support rod and a base plate, wherein the handrail frame is fixed with the connection frame through a linear bearing, the flat type microcomputer is installed on the connection frame through a support seat, the connection frame is arranged on the base plate through the S-shaped support rod, a control box is arranged on the base plate, and an environmental self-adaption module, a motion intention identification module, a speed control module, a falling prevention module and a motor driving module are loaded on the flat type microcomputer. The recovery walking aiding robot can automatically adapt to complex external environments, can achieve the functions of detecting and avoiding obstacles, preventing sliding and the like, provides falling prevention, and solves contradiction between dyskinesia of users and operation requirements of the robot.

Piperidine Compounds; compositions comprising a Piperidine Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperidine Compound are disclosed. In one embodiment, the Piperidine Compound has the formula: and pharmaceutically acceptable salts thereof, wherein Ar1, Ar2, X, R3, R4, and m are as disclosed herein.

The present invention is concerned with compounds of the general Formula I:and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.

The present application provides sodium channel blockers exemplified by the following structure:The compounds of the invention useful for treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, and chronic diverticulitis, for example.

The invention relates to a robot system based on a brain-computer interface and an implementation method. The robot system is mainly characterized in that a brain-computer interface sub-system obtains a brain electrical signal through a measurement electrode and performs feature extraction of the brain electrical signal to obtain the intention of a user; the brain-computer interface sub-system converts the intention of the user into a control command and transmits the control command to a robot sub-system through a communication sub-system; the robot sub-system receives the control command of the brain-computer interface sub-system and controls a robot to move; the robot sub-system transmits video information acquired by self to the brain-computer interface sub-system; and the brain-computer interface sub-system forms a stimulation interface fed back to the user. According to the invention, mobility control of the robot in eight directions through the steady-state visual evoked potential brain-computer interface can be realized; furthermore, the system can control the robot rapidly and precisely without being trained; because the brain-computer interface is free from body movement participation, the user suffering from severe dyskinesia can move to an expected position; and thus, the living quality is increased.

The invention discloses a recombinant vector for the knock-in of a human Huntington gene, a construction method of the recombinant vector and application of the recombinant vector in the constructionof a model pig. According to the recombinant vector, a human mutated Huntington exon gene is knocked in a fixed point manner for the first time, a virulence gene is knocked in by virtue of a CRISPR / Cas9 technique for the first time, and a donor vector is optimized by optimizing sfRNA, so that the probability that the gene is knocked into a positive cloned cell is increased; and by combining with apig cell nucleus transplantation technique, the probability that a directly obtained positive cell is knocked into the pig is increased, and a small human Huntington gene knock-in pig is obtained, thereby proving the efficient feasibility of the method for constructing gene modified pigs. The constructed Huntington gene knock-in model pig has behavioral characteristics such as respiratory disturbance and dyskinesia similar to human Huntington diseases, and stable heritable passage can be realized, so that a reliable model is provided for the research of the human Huntington diseases; and thenumber can be guaranteed so as to realize drug screening, gene treatment, stem cell treatment and the like, and the model can be a good human disease model.

Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and / or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and / or Parkinson's disease or any combinations.

Fluorine-containing amino acid derivatives represented general formula (I), pharmaceutically acceptable salts thereof or hydrates of the same, wherein X1 represents hydrogen or fluorine; and R1 and R2 are the same or different and each represents hydrogen or lower C1-10 alkyl. These compounds are useful as drugs, in particular, group 2 metabotropic glutamate receptor agonists for treating and preventing psychiatric disorders such as schizophrenia, anxiety and associated diseases, depression, bipolar disturbance and epilepsy, and neurological diseases such as drug addiction, cognition disorder, Alzheimer's disease, Huntington's chorea, Parkinson's disease, motility disturbance associating muscular stiffness, cerebral ischemia, cerebral insufficiency, spinal cord lesion and head disturbance.

A Compound of formula (wherein X is O or S and R<1>-R<5 >are disclosed herein) or a pharmaceutically acceptable salt thereof (each being a "Piperazine Compound"), pharmaceutical compositions comprising a Piperazine Compound and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperazine Compound are disclosed.

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, tinnitus, and status epilepticus.

The invention provides novel isomers of dihydrotetrabenazine, individual enantiomers and mixtures thereof wherein the dihydrotetrabenazine is a 3,11 b-cis-dihydrotetrabenazine. Also provided are methods for the preparation of the novel isomers, pharmaceutical compositions containing them and their use in treating hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome.

The invention discloses a joint compound motion mechanical arm used for rehabilitation training of an upper limb. The mechanical arm comprises a base, an electric lifting column, a T type supporting frame, a main fixed base and an outer skeleton mechanical arm system, wherein the base is placed on the ground; the electric lifting column is fixedly connected with the base; the electric lifting column is fixedly connected with the T type supporting frame; the main fixed base is mounted on a supporting frame; the outer skeleton mechanical arm system is connected with driving motors through the main fixed base; and the driving motors are all mounted on the main fixed base. When the mechanical arm is in use, only the outer skeleton mechanical arm system moves according to a control instruction; the motors are motionless relative to the base; the mechanical arm is light, convenient and flexible, creative in structure, small in occupied space, and stable and reliable in movement; the joint compound motion mechanical arm can be used for assisting a patient with upper limb dyskinesia to finish all kinds of rehabilitation training actions; and meanwhile, the mechanical arm can be used for single-joint rehabilitation training for a shoulder joint and an elbow joint, and also can be used for compound motion rehabilitation training for multiple joints of the upper limb.

The present invention describes a novel treatment for movement disorders, including tardive dyskinesia, tic disorders, Tourette's syndrome, and blepharospasm, and other focal dystonias. The treatment of the present invention utilizes agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.

The invention discloses a quantization evaluating device and method for dyskinesia symptoms of Parkinson and related extrapyramidal diseases. The device comprises an S-shaped gait channel, a finger inertia element node, a body inertia element node, a high-speed image collection unit, a central computer, an inertia element synchronization box, a synchronization state lamp, a wireless router, a switch and a power supply. The method comprises the steps of starting initialization of devices and starting the devices, adding basic information of testing personnel or searching existing testing personnel, selecting a collection mode, synchronizing a data collection unit module, collecting, displaying and storing data under assigned actions in real time, analyzing the data, and storing and printing quantization evaluating results. According to the quantization evaluating device and method for the dyskinesia symptoms of the Parkinson and related extrapyramidal diseases, the subjective evaluating method depending on the experiment of clinicians is thoroughly changed, and the device and method have improved theoretical value and realistic guidance significance on treatment of patients with dyskinesia, making of rehabilitation schemes and judgment of the curative effect and a prognosis.

The present invention relates to a brain-machine interface system based on face recognition specific wave N170 component, which implements sorting of facial pictures and object pictures, and comprises a picture stimulator, a cortical electric signal collector, a face recognition specific wave N170 detector, and a picture sorter. Pictures to be sorted are presented by the visual picture stimulator as visual stimulations to a user, and the cortical electric signals of the user generated in response are recorded and subjected to amplification and A / D conversion, and then processed and analyzed by the face recognition specific wave N170 detector, whereby a determination is made whether the collected cortical electric signals contain specific wave N170 component related to facial picture stimulation, and accordingly, the cortical electric signals are transformed into picture sorting control commands for identifying facial pictures and object pictures. The advantages of the present invention are: the present invention utilizes the specific cortical electric signal N170 component generated in the facial picture recognition process in response to facial picture stimulations, and employs an effective online feature extraction and sorting algorithm in the cortical electric signal analyzer; therefore, the discrimination ratio of the system is increased. The present invention provides a novel means for persons who suffer from dyskinesia but can think normally to communicate with and control the external environment.

The invention relates to a control method in the information processing technical field, in particular to an asynchronous brain-computer interactive control method for an EEG signal. The method comprises the following steps: acquiring EEG signal data under a continuous motion imagery condition; re-sampling training data; extracting features and establishing a classifier model; carrying out on-line feature projection and pattern classification; calculating duration time in a current status according to dynamic change of the duration time by a post-processing technology; and forming closed brain-computer interactive control by asynchronous brain-computer interactive control and neural feedback. The asynchronous brain-computer interactive control method reduces interactive retardance, improves fault-tolerant capability, breaks through a discrete command control mode, and enhances brain-computer interactive flexibility, and can provide a direct brain-computer interactive communication technology for the handicapped or patients with dyskinesia.

Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and / or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.

The present invention relates to an automated method of determining a kinetic state of a person. The method obtains accelerometer data from an accelerometer worn on an extremity of the person and processes the accelerometer data to determine a measure for the kinetic state. The present invention further relates to a device for determining a kinetic state of a person. The device comprises a processor configured to process data obtained from an accelerometer worn on an extremity of the person and to determine from the data a measure for the kinetic state. In the method and system the kinetic state is at least one of bradykinesia, dyskinesia, and hyperkinesia.

The invention relates to the technical field of medical rehabilitation instruments and specifically to an intelligent upper limb rehabilitation training device. The main structure comprises a controller, a detection module, a power driving device and a training device mechanism. The intelligent upper limb rehabilitation training device formed through the matching of the parts is suitable for rehabilitation training / training aiding of patients suffering from upper limb dyskinesia caused by hemiplegia and / or other factors, is especially suitable for the patients suffering from functional disorder of upper limbs, and can provide passive, active and / or resisting training according to the requirements of different patients and achieve an effect of targeted rehabilitation. During use, the device can guarantee accurate location and be attached to each joint of the upper limbs, thereby preventing the tissue damage and muscle strain caused by wrong practices. The intelligent upper limb rehabilitation training device is simple in structure, small in size, light in mass, convenient to use, good in training effect, high in training accuracy, low in manufacture cost and wide in application range.